Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?

References

• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434.
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176–198.
   PubMed Web of Science ®Google Scholar
• Arnedos M, Bihan C, Delaloge S, et al. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol. 2012;4:195–210.
   PubMedGoogle Scholar
• Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007;109:1721–1728.
   PubMed Web of Science ®Google Scholar
• Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011;29:3885–3891.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–1220.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541–1557.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen international consensus guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216–1235.
   PubMedGoogle Scholar
• Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28:1700–1712.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology. Breast Cancer. V02·2022. 2022 Febraury 2022 https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
   Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–172.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Untch M, Blohmer J-U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–1804.
   PubMed Web of Science ®Google Scholar
• FDA. FDA guidance documents: pathologic complete response neoadjuvant treatment high risk early stage breast cancer use endpoint. https://www.fda.gov/media/83507/download
   Google Scholar
• Masuda N, Lee S-J, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–2159.
   PubMed Web of Science ®Google Scholar
• Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer. N Engl J Med. 2021;384:2394–2405.
   PubMed Web of Science ®Google Scholar
• Sharma P, López-Tarruella S, García-Saenz JA, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts. Clin Cancer Res. 2017;23:649–657.
   PubMed Web of Science ®Google Scholar
• Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497–1508.
   PubMed Web of Science ®Google Scholar
• Fountzila E, and Ignatiadis M. Neoadjuvant immunotherapy in breast cancer: a paradigm shift? Ecancermedicalscience. 2020;14: 1147.
   PubMed Web of Science ®Google Scholar
• Keenan TE, Tolaney SM. Role of Immunotherapy in triple-negative breast cancer. J Natl Compr Cancer Netw. 2020;18:479–489.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, and Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med [Internet]. 2018;379:2108–2121.
   PubMed Web of Science ®Google Scholar
• Emens LA, Adams S, and Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: iMpassion130 final overall survival analysis. Ann Oncol .2021;32:983–993.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Schmid P, Cescon DW, et al. Abstract GS3-01: additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. Gen Sess Abstr. 2021; GS3-01-GS3–01. American Association for Cancer Research.
   Google Scholar
• Cortes J, Cescon DW, and Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet . 2020;396:1817–1828.
   PubMed Web of Science ®Google Scholar
• Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer—expanded options, evolving needs. Nat Rev Clin Oncol [Internet]. 2021; Available from: https://www.nature.com/articles/s41571-021-00565-2. .
   PubMedGoogle Scholar
• Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:80.
   Google Scholar
• Tarantino P, Gandini S, Trapani D, et al. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2021;159:103223.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, and Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med . 2020;382:810–821.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, and Dent R, et al. VP7-2021: KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol . 2021;32:1198–1200.
   Web of Science ®Google Scholar
• Schmid P, Cortes J, and Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med . 2022;386:556–567. . .
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves pembrolizumab high risk early stage triple negative breast cancer Accessed 10 January 2022 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer.
   Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361–370.
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23:2965–2970.
   PubMed Web of Science ®Google Scholar
• Luen S, Virassamy B, Savas P, et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241–250.
   PubMed Web of Science ®Google Scholar
• Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021;11:1353–1367.
   PubMed Web of Science ®Google Scholar
• Nanda R, Liu MC, and Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer. JAMA Oncol . 2020;6:676. . . .
   PubMed Web of Science ®Google Scholar
• Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. 2020;31:569–581.
   PubMed Web of Science ®Google Scholar
• Gianni L, Huang C-S, and Egle D, et al. Abstract GS3-04: pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res. 2020 80 (4_Supplement) ; Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR.:GS3–04.
   Google Scholar
• Bianchini G, Huang C-S, Egle D, et al. LBA13 – tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol. 2020;31:S1142–S1215.
   Google Scholar
• Kim SI, Cassella CR, and Byrne KT. Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes. Front Immunol. 2021 11 ;629722 .
   PubMed Web of Science ®Google Scholar
• Gonzalez‐Ericsson PI, Stovgaard ES, Sua LF, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020;250:667–684.
   PubMed Web of Science ®Google Scholar
• Miglietta F, Griguolo G, Guarneri V, et al. Programmed cell death ligand 1 in breast cancer: technical aspects, prognostic implications, and predictive value. Oncologist. 2019;24:e1055–e1069.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tria. Lancet. 2020;396:1090–1100. .
   PubMed Web of Science ®Google Scholar
• ESMO. Withdrawal of application to change the marketing authorisation for atezolizumab.
   Google Scholar
• Giugliano F, Antonarelli G, and Tarantino P, et al. Harmonizing PD-L1 testing in metastatic triple negative breast cancer. Expert Opin Biol Ther. 2022;22:345–348.
   PubMedGoogle Scholar
• Loibl S, Schneeweiss A, Huober JB, et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol. 2021;39:506–506.
   Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30:1279–1288.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2–positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983–991.
   PubMed Web of Science ®Google Scholar
• Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37:559–569.
   PubMed Web of Science ®Google Scholar
• Van Bockstal MR, François A, Altinay S, et al. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Mod Pathol. 2021;34:2130–2140.
   PubMedGoogle Scholar
• Kossai M, Radosevic-Robin N, Penault-Llorca F. Refining patient selection for breast cancer immunotherapy: beyond PD-L1. ESMO Open. 2021;6:100257.
   PubMedGoogle Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44–56.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Jain E, Cohen O, et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 2020;31:387–394.
   PubMed Web of Science ®Google Scholar
• O’Meara TA, Tolaney SM. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget. 2021;12:394–400.
   PubMedGoogle Scholar
• Karn T, Denkert C, Weber KE, et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020;31:1216–1222.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Bautista R, Caro-Sánchez CH, and Cabrera-Galeana P, et al. Immune milieu and genomic alterations set the triple-negative breast cancer immunomodulatory subtype tumor behavior. Cancers (Basel) . 2021;13:6256.
   PubMedGoogle Scholar
• Foldi J, Silber A, Reisenbichler E, et al. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer. 2021;7:9.
   PubMed Web of Science ®Google Scholar
• Iwase T, Blenman KRM, Li X, et al. A novel immunomodulatory 27-gene signature to predict response to neoadjuvant immunochemotherapy for primary triple-negative breast cancer. Cancers (Basel). 2021;13:4839.
   PubMedGoogle Scholar
• Campbell M, Yau C, and Borowsky A, et al. Abstract PD6-08: analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial. Cancer Res. Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA). 2018 78 (4_Supplement): PD6–08 ; Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA).
   Google Scholar
• Soliman H, Wolf D, Yau C, et al. Chemokine12 (Chk12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL – pembrolizumab with and without SD101, and durvalumab combined with olaparib – and in 9 other arms of the t. SABC. 2021;862:D10–07. Abstract #.
   Google Scholar
• Isaacs J, Anders C, McArthur H, et al. Biomarkers of immune checkpoint blockade response in triple-negative breast cancer. Curr Treat Options Oncol. 2021;22:38.
   PubMedGoogle Scholar
• Loibl S, Sinn B, and Karn T, et al. Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC) – results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial. Cancer Res. 2019 79 (4_Supplement) PD2–07 ; . .
   Google Scholar
• Bianchini G, Dugo M, Huang C-S, et al. LBA12 Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial. Ann Oncol. 2021;32:S1283–S1284.
   Google Scholar
• Johnson DB, Estrada MV, Salgado R, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018;36:942–950.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, et al. Tumor-specific major histocompatibility-ii expression predicts benefit to anti–PD-1/L1 Therapy in patients with HER2-negative primary breast cancer. Clin Cancer Res. 2021;27:5299–5306.
   PubMed Web of Science ®Google Scholar
• Pesapane F, Rotili A, and Botta F, et al. Radiomics of MRI for the prediction of the pathological response to neoadjuvant chemotherapy in breast cancer patients: a single referral centre analysis. Cancers (Basel). 2021;13:4271.
   PubMedGoogle Scholar
• Heinhuis KM, Ros W, Kok M, et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30:219–235.
   PubMed Web of Science ®Google Scholar
• Bracci L, Schiavoni G, Sistigu A, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21:15–25.
   PubMed Web of Science ®Google Scholar
• Ma Y, Mattarollo SR, Adjemian S, et al. CCL2/CCR2-Dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res. 2014;74:436–445.
   PubMed Web of Science ®Google Scholar
• McDonnell AM, Lesterhuis WJ, Khong A, et al. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol. 2015;45:49–59.
   PubMedGoogle Scholar
• Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003;170:4905–4913.
   PubMed Web of Science ®Google Scholar
• Machiels J-PH, Todd Reilly R, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001;61:3689–3697.
   PubMed Web of Science ®Google Scholar
• Pfannenstiel LW, Lam SSK, Emens LA, et al. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol. 2010;263:79–87.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–648.
   PubMed Web of Science ®Google Scholar
• Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35:2647–2655.
   PubMed Web of Science ®Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920–928.
   PubMed Web of Science ®Google Scholar
• Ding W, Li Z, Wang C, et al. Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer. Medicine (Baltimore). 2018;97:e12908.
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32:994–1004.
   PubMed Web of Science ®Google Scholar
• Dent R, Rugo HS. Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum. Lancet Oncol. 2021;22:27–28.
   PubMedGoogle Scholar
• Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:497–509.
   PubMed Web of Science ®Google Scholar
• Song Z, Wang H, Yang Q, et al. 181P Pegylated liposomal doxorubicin (PLD) combined with docetaxel and trastuzumab in neoadjuvant treatment for HER2-positive breast cancer: a multicenter, randomized, phase II, open-label trial. Ann Oncol. 2021;32:S437.
   PubMedGoogle Scholar
• Loibl S, Sikov WM, Huober J, et al. 119O - Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: brighTNess, a randomize. Ann Oncol. 2021;32:S407–S446.
   Google Scholar
• Sharma P, Kimler BF, O’Dea A, et al. Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I–III triple-negative breast cancer (NeoSTOP). Clin Cancer Res. 2021;27:975–982.
   PubMedGoogle Scholar
• Conte PF, Dieci MV, and Bisagni G, et al. Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: the A-BRAVE trial. J Clin Oncol . 2020;38 15_suppl :TPS598.
   Google Scholar
• Pusztai L, Barlow W, and Ganz P, et al. Abstract OT1-02-04: SWOG S1418/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy. Cancer Res . American Association for Cancer Research; 2018 78 (4_Supplement). OT1-02–04. .
   Google Scholar
• Gavalas NG, Tsiatas M, Tsitsilonis O, et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer. 2012;107:1869–1875.
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73:539–549.
   PubMed Web of Science ®Google Scholar
• Coukos G, Benencia F, Buckanovich RJ, et al. The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer. 2005;92:1182–1187.
   PubMed Web of Science ®Google Scholar
• Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70:6171–6180.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
   PubMed Web of Science ®Google Scholar
• Lee WS, Yang H, Chon HJ, et al. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52:1475–1485.
   PubMed Web of Science ®Google Scholar
• Makker V, Colombo N, and Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022 386(5);437–448 .
   Google Scholar
• Yi M, Jiao D, Qin S, et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60.
   PubMed Web of Science ®Google Scholar
• Suyama K, Iwase H. Lenvatinib. Cancer Control. 2018;25:107327481878936.
   Web of Science ®Google Scholar
• Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9:105.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*. Oncotarget. 2015;6:22496–22512.
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–1541.
   PubMed Web of Science ®Google Scholar
• Coats S, Williams M, Kebble B, et al. Antibody–drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res. 2019;25:5441–5448.
   PubMed Web of Science ®Google Scholar
• Gerber H-P, Sapra P, Loganzo F, et al. Combining antibody–drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol. 2016;102:1–6.
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–763.
   PubMed Web of Science ®Google Scholar
• Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–533.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20:e175–e186.
   PubMed Web of Science ®Google Scholar
• Lassen U. Combining PARP inhibition with PD-1 inhibitors. Lancet Oncol. 2019;20:1196–1198.
   PubMedGoogle Scholar
• Domchek SM, Postel-Vinay S, Im S-A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155–1164.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39:989–998.e5.
   PubMed Web of Science ®Google Scholar
• Patel JM, Goss A, Garber JE, et al. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. Npj Breast Cancer. 2020;6:19.
   PubMedGoogle Scholar
• Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4/6 Inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23:5561–5572.
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471–475.
   PubMed Web of Science ®Google Scholar
• Deng J, Wang ES, Jenkins RW, et al. CDK4/6 Inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8:216–233.
   PubMed Web of Science ®Google Scholar
• Goel S, Tolaney SM. CDK4/6 inhibitors in breast cancer: a role in triple-negative disease? Lancet Oncol. 2019;20:1479–1481.
   PubMedGoogle Scholar
• Tan AR, Wright GS, Thummala AR, et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2019;20:1587–1601.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Ruby CE, Hughes T, et al. Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11.
   PubMedGoogle Scholar
• Liu BL, Robinson M, Han Z-Q, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10:292–303.
   PubMed Web of Science ®Google Scholar
• Kai M, Marx AN, Liu DD, et al. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep. 2021;11:22242.
   PubMedGoogle Scholar
• Soliman H, Hogue D, Han H, et al. A phase I trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer. Clin Cancer Res. 2021;27:1012–1018.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hodi FS, Weber JS, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291:1–13.
   PubMed Web of Science ®Google Scholar
• Czystowska M, Han J, Szczepanski MJ, et al. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ. 2009;16:708–718.
   PubMed Web of Science ®Google Scholar
• Chung AW, Anand K, and Anselme AC, et al. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021;13:624.
   Google Scholar
• Levy R, Reagan PM, Friedberg JW, et al. SD-101, a Novel Class C CpG-oligodeoxynucleotide (ODN) toll-like receptor 9 (TLR9) agonist, given with low dose radiation for untreated low grade B-cell lymphoma: interim results of a phase 1/2 trial. Blood. 2016;128:2974–2974.
   Google Scholar
• Lee DH. Update of early phase clinical trials in cancer immunotherapy. BMB Rep. 2021;54:70–88.
   PubMedGoogle Scholar
• Wang-Gillam A, O’Reilly EM, Bendell JC, et al. A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2019;37: TPS465.
   PubMedGoogle Scholar
• Sabel MS, Nehs MA, Su G, et al. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat. 2005;90:97–104.
   PubMed Web of Science ®Google Scholar
• Shiao SL, Coussens LM. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia. 2010;15:411–421.
   PubMed Web of Science ®Google Scholar
• Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11:728–734.
   PubMed Web of Science ®Google Scholar
• McArthur HL, Diab A, Page DB, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res. 2016;22:5729–5737.
   PubMed Web of Science ®Google Scholar
• McArthur HL, Shiao S, and Karlan S, et al. Abstract PD10-01: The PEARL trial: Pre-operative pembrolizumab with radiation therapy in early stage triple negative breast cancer. Cancer Res. 2022;82(4 Suppl):PD10–01.
   Google Scholar
• Corti C, Giachetti PPMB, Eggermont AMM, et al. Therapeutic vaccines for breast cancer: has the time finally come? Eur J Cancer. 2022;160:150–174.
   PubMed Web of Science ®Google Scholar
• Zacharakis N, Huq LM, and Seitter SJ, et al. Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J Clin Oncol . 2022;40:16;1741–1754 .
   Google Scholar
• Hutchins LF, Makhoul I, Emanuel PD, et al. Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects. Oncotarget. 2017;8:99161–99178.
   PubMedGoogle Scholar
• Bonehill A, Tuyaerts S, Van Nuffel AM, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 2008;16:1170–1180.
   PubMed Web of Science ®Google Scholar
• De Keersmaecker B, Claerhout S, Carrasco J, et al. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. J Immunother Cancer. 2020;8:e000329.
   PubMedGoogle Scholar
• Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003;21:3343–3350.
   PubMed Web of Science ®Google Scholar
• Bernal-Estévez DA, Ortíz Barbosa MA, and Ortíz-Montero P, et al. Autologous dendritic cells in combination with chemotherapy restore responsiveness of T cells in breast cancer patients: a single-arm phase I/II trial. Front Immunol. 2021;12 :669965.
   PubMedGoogle Scholar
• O’Shaughnessy J, Roberts LK, Smith JL, et al. Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts). J Clin Oncol. 2016;34:1086–1086.
   Web of Science ®Google Scholar
• Dieci MV, Griguolo G, and Bottosso M, et al. Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. Npj Breast Cancer]. 2021;7:101.
   PubMedGoogle Scholar
• Conforti F, Pala L, and Sala I, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021 375 ;e066381.
   PubMedGoogle Scholar
• Buyse M, Molenberghs G, Burzykowski T, et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1:49–67.
   PubMedGoogle Scholar
• Symmans WF, Peintinger F, and Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414–4422.
   PubMed Web of Science ®Google Scholar
• Yau C, Osdoit M, and van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol . 2022;23:149–160.
   PubMed Web of Science ®Google Scholar
• Symmans WF, Wei C, and Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol . 2017;35:1049–1060.
   PubMed Web of Science ®Google Scholar
• Nicolò E, Giugliano F, and Ascione L, et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev . 2022;106:102395.
   PubMed Web of Science ®Google Scholar